文献速递类风湿关节炎其他结缔组织病

肺超声检测类风湿关节炎间质性肺异常影像学进展

Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2026-05-03

这项前瞻性先导研究纳入81例类风湿关节炎患者,在基线和12至18个月后行高分辨率CT、肺功能、症状评估和72区肺超声。31%出现影像学进展,B线增加与进展显著相关,基线B线及B线变化可预测进展(AUC 0.78),联合一氧化碳弥散量变化后AUC 0.82。

要点

  • 肺超声B线增加与类风湿关节炎间质性肺异常影像学进展显著相关。
  • 基线B线及B线随时间变化均可独立预测影像学进展。
  • 肺超声联合一氧化碳弥散量变化预测效能优于症状评分和肺功能。

核心结论

  • 肺超声可能是有用的无辐射工具,用于监测和预测类风湿关节炎间质性肺异常的影像学进展。

研究设计与样本

  • 前瞻性先导研究,81例类风湿关节炎患者完成随访高分辨率CT,95%(77/81)按方案完成肺超声。
  • 基线和12至18个月后行高分辨率CT、肺功能、症状评估和72区肺超声,影像学变化由盲法胸部放射科医生采用五点Likert量表评分。
  • 构建六个多变量逻辑回归模型,使用肺超声参数、肺功能、症状和临床特征的组合预测高分辨率CT进展。

主要发现

  • 31%(25/81)观察到影像学进展。
  • B线增加与影像学进展显著相关(P=0.018),并确认线性趋势(P=0.026)。
  • 多变量分析中,基线B线(P=0.029)和B线随时间变化(P=0.012)均显著预测进展(AUC 0.78,95%CI 0.64-0.92)。
  • 联合肺超声和一氧化碳弥散量变化(AUC 0.82,95%CI 0.70-0.94)模型拟合相似,且优于症状评分(AUC 0.58,95%CI 0.40-0.75,P=0.020)和肺功能(AUC 0.59,95%CI 0.44-0.74,P=0.022)。

关键数值与推荐

  • B线采用72区方案量化。
  • 影像学变化采用五点Likert量表评分。
  • 肺超声联合一氧化碳弥散量变化预测影像学进展的AUC为0.82(95%CI 0.70-0.94)。

临床怎么用

  • 肺超声可作为类风湿关节炎患者间质性肺异常纵向评估的无辐射监测工具,尤其作为多模式方法的一部分。

局限性

  • 研究为先导性设计,样本量有限,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) is an important extra-articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung abnormalities (ILAs). METHODS: In this prospective pilot study, patients with RA underwent high-resolution computed tomography (HRCT), pulmonary function tests (PFTs), symptom assessment, and LUS at baseline and 12 to 18 months later. B-lines were quantified using a 72-zone protocol. Radiologic changes across longitudinal HRCTs were scored on a five-point Likert scale by blinded thoracic radiologists. Six multivariable logistic regression models were built to predict HRCT progression using combinations of LUS parameters, PFTs, symptoms, and clinical characteristics. RESULTS: Eighty-one patients completed the follow-up HRCT, and per-protocol LUS was performed in 95% (77/81). Radiologic progression was observed in 31% (25/81). An increase in B-lines was significantly associated with radiologic progression (P = 0.018), and a linear trend was confirmed (P = 0.026). In multivariable analysis, both baseline B-lines (P = 0.029) and the change in B-lines over time (P = 0.012) significantly predicted progression (area under the curve [AUC] 0.78, 95% confidence interval [CI] 0.64-0.92). When combining LUS and change in diffusing capacity for carbon monoxide (AUC 0.82, 95% CI 0.70-0.94), the model fit remained similar and outperformed symptom scores (AUC 0.58, 95% CI 0.40-0.75, P = 0.020) and PFTs (AUC 0.59, 95% CI 0.44-0.74, P = 0.022). CONCLUSION: LUS may be a useful, radiation-free tool to monitor and predict radiologic progression of ILAs in RA. These findings support further research into integrating LUS into longitudinal RA-ILD assessment, particularly as part of a multimodal approach.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Vermant M, Van Ballaer V, Jacob J, et al. Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2026. PMID: 41930622. doi:10.1002/art.70161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。